Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06414889 · ClinicalTrials.gov registry record · Phase 1
Protocol Title: Safety and Feasibility of Autologous CD34+ Hematopoietic Stem Cells Mobilization and Apheresis in Participants With RUNX1 Familial Platelet Disorder
A Phase 1 study of RUNX1 Familial Platelet Disorder, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
- 1
- Study location
NCT06414889: Recruiting Phase 1 study of RUNX1 Familial Platelet Disorder, sponsored by M.D. Anderson Cancer Center.
NCT06414889 is a Phase 1 study of RUNX1 Familial Platelet Disorder that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 4 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06414889, a Phase 1 study of RUNX1 Familial Platelet Disorder, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
- 1
- Study location
Study Summary
To evaluate the safety and feasibility of collecting hematopoietic stem cells (HSC) in participants with RUNX1-FPD.
Primary Outcome
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Conditions Studied
Interventions
- DRUG G-CSF (filgrastim or biosimilar)
- PROCEDURE Apheresis
- DRUG Plerixafor
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2024-05-20 |
| Est. Completion | 2027-06-30 |
| Phase | Phase 1 |
What NCT06414889 shows while recruiting
NCT06414889 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (93% lower).
The record links to 1 condition, with RUNX1 Familial Platelet Disorder appearing as the primary indexed condition, and to 3 interventions - of which G-CSF (filgrastim or biosimilar) is the first listed.
NCT06414889 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06414889 about?
NCT06414889 is a clinical study titled "Protocol Title: Safety and Feasibility of Autologous CD34+ Hematopoietic Stem Cells Mobilization and Apheresis in Participants With RUNX1 Familial Platelet Disorder". To evaluate the safety and feasibility of collecting hematopoietic stem cells (HSC) in participants with RUNX1-FPD.
What is the current status of trial NCT06414889?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2024-05-20. Estimated completion is 2027-06-30.
What conditions does trial NCT06414889 study?
This clinical trial studies the following conditions: RUNX1 Familial Platelet Disorder.
What interventions are being tested in trial NCT06414889?
The interventions under investigation include: G-CSF (filgrastim or biosimilar) (DRUG), Apheresis (PROCEDURE), Plerixafor (DRUG).
Who is sponsoring clinical trial NCT06414889?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06414889 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06414889's enrollment target sits among peer trials
4 1996th of 2000 higher than 2 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI